Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: Clinical and magnetic resonance imaging findings

Multiple Sclerosis Journal

Volumn 18, Issue 11, 2012, Pages 1640-1643

  Rinaldi, F ^a   Seppi, D ^a   Calabrese, M ^a   Perini, P ^a   Gallo, P ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

fingolimod; Multiple sclerosis; natalizumab

Indexed keywords

FINGOLIMOD; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB; PROPANEDIOL DERIVATIVE; SPHINGOSINE; VIRUS ANTIBODY;

ADULT; ANALOGS AND DERIVATIVES; BLOOD; DISABILITY; DRUG ADMINISTRATION; DRUG SUBSTITUTION; FEMALE; HUMAN; IMMUNOLOGY; JC VIRUS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE IMAGING; TIME; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868036448     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512464282     Document Type: Article

References (11)

1. O'Connor PW, Goodman AD, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
2. Stuve O, Cravens PD, Frohman EM, et al. Immunologic and clinical status 14 months after cessation of natalizumab therapy. Neurology. 2009 ; 72: 396-401
3. Vellinga MM, Castelijns JA, Barkhof F, et al. Post withdrawal rebound increase T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008 ; 70: 1150-1151 (Pubitemid 351464749)
4. West TW, Cree BA. Natalizumab dosage suspension: are we helping or hurting?. Ann Neurol. 2010 ; 68: 395-399
5. Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011 ; 308: 98-102
6. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010 ; 68: 295-303
7. Lancet Neurol. Kappos L Bates D Edan G, ed. 2011: 745-758.
8. Mult Scler. Sorensen PS Bertolotto A Edan G, ed. 2012: 143-152.
9. Khatri BO, Man S, Giovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009 ; 72: 402-409
10. Schmouder R, Hariry S, David OJ. Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers. Eur J Clin Pharmacol. 2012 ; 68: 355-362
11. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 ; 355: 1124-1140 (Pubitemid 44394919)